The abstract is read at the publisher; the summary is JClub's.
CGRP links historical neurogenic inflammation in mammal and human skin to modern migraine therapy, and CGRP-targeting drugs have transformed prevention and acute treatment.
- Why it matters: The field needed a mechanistic bridge between early neurophysiology—antidromic activation causing flare and sensitization—and current drug targets for migraine.
- What they did: The work synthesizes evidence from neurogenic inflammation in skin and the development of multiple monoclonal antibodies against CGRP or its receptor plus orally available small-molecule CGRP receptor antagonists.
- The result: Pharmacokinetics and CGRP’s paracrine actions support a spatially limited peripheral microenvironment outside the blood-brain barrier involving C-fibre nociceptors, Aδ-fibres, vascular smooth muscle cells, and Schwann cells.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.